Ninety‐Six–Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV‐1 and Wild‐Type Hepatitis B Virus | Zendy

Firouzé BaniSadr | Zendy; Pierre Palmer | Zendy; Catherine Scieux | Zendy; JeanMichel Molina | Zendy

Open Access

Ninety‐Six–Week Efficacy of Combination Therapy with Lamivudine and Tenofovir in Patients Coinfected with HIV‐1 and Wild‐Type Hepatitis B Virus

Author(s) -

Firouzé BaniSadr,

Pierre Palmer,

Catherine Scieux,

JeanMichel Molina

Publication year - 2004

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/424012

Subject(s) - lamivudine , medicine , coinfection , virology , hepatitis b virus , combination therapy , hepatitis b , tenofovir , virus , human immunodeficiency virus (hiv) , sida , viral disease

We describe 6 patients who were coinfected with human immunodeficiency virus (HIV) type 1 and wild-type hepatitis B virus (HBV), in whom complete and sustained antiviral activity against wild-type HBV strains was attained during 96 weeks of combination therapy with lamivudine and tenofovir. The use of combination therapy with lamivudine and tenofovir for the treatment of HBV infection is very promising in the treatment of HIV/HBV coinfection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research